share_log

HENGRUI PHARMA: NOTICE OF BOARD MEETING

HKEX ·  Oct 13, 2025 16:30

Summary by Futu AI

江蘇恒瑞醫藥股份有限公司於2025年10月13日宣佈,將於2025年10月27日(星期一)召開董事會會議,主要議程為審議及批准公司及其附屬公司截至2025年9月30日止九個月的季度業績,並討論相關業績發佈事宜。本次會議由董事長孫飄揚先生召集,現任董事會成員包括6名執行董事、1名非執行董事及4名獨立非執行董事。
江蘇恒瑞醫藥股份有限公司於2025年10月13日宣佈,將於2025年10月27日(星期一)召開董事會會議,主要議程為審議及批准公司及其附屬公司截至2025年9月30日止九個月的季度業績,並討論相關業績發佈事宜。本次會議由董事長孫飄揚先生召集,現任董事會成員包括6名執行董事、1名非執行董事及4名獨立非執行董事。
Hengrui Pharma announced on October 13, 2025, that it will convene a board meeting on October 27, 2025 (Monday). The primary agenda will include reviewing and approving the quarterly financial results of the company and its subsidiaries for the nine months ended September 30, 2025, as well as discussing matters related to the release of these results.This meeting has been convened by Chairman Sun Piaoyang. The current board members comprise six executive directors, one non-executive director, and four independent non-executive directors.
Hengrui Pharma announced on October 13, 2025, that it will convene a board meeting on October 27, 2025 (Monday). The primary agenda will include reviewing and approving the quarterly financial results of the company and its subsidiaries for the nine months ended September 30, 2025, as well as discussing matters related to the release of these results.This meeting has been convened by Chairman Sun Piaoyang. The current board members comprise six executive directors, one non-executive director, and four independent non-executive directors.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.